BAAM
FATE icon

Baker Avenue Asset Management’s Fate Therapeutics FATE Stock Holding History

Baker Avenue Asset Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-46
Closed -$219 – 1625
2023
Q2 		$219 Buy
+46
New +$254 ﹤0.01% 1563
2019
Q4 		– Sell
-20,000
Closed -$310K – 260
2019
Q3 		$310K Hold
20,000
– – 0.02% 205
2019
Q2 		$406K Hold
20,000
– – 0.03% 186
2019
Q1 		$351K Buy
+20,000
New +$316K 0.03% 207

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Baker Avenue Asset Management's FATE Position: Q3 2023 in Review

Baker Avenue Asset Management sold out of Fate Therapeutics (FATE) in Q3 2023, closing a stake of 46 shares — an estimated $219 sold.

Baker Avenue Asset Management first reported a position in FATE in Q1 2019 and held it in 4 quarters. The position peaked at $406K in Q2 2019. 170 funds tracked by Wall St. Rank hold FATE as of Q3 2023.

  • Baker Avenue Asset Management reported no remaining Fate Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Baker Avenue Asset Management sold 46 Fate Therapeutics shares in Q3 2023, an estimated $219.
  • Baker Avenue Asset Management first reported a position in Fate Therapeutics in Q1 2019 and held it in 4 quarters.
  • Baker Avenue Asset Management's Fate Therapeutics position peaked at $406K in Q2 2019.
  • 170 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2023.

Based on Baker Avenue Asset Management's 13F filing for Q3 2023, filed 15 Nov 2023.